Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2005

View Archived Issues

Levetiracetam improves chorea symptoms in patients with Huntington's disease

Ralfinamide induces analgesic effects in patients with neuropathic pain

VasoGenix and QLT to develop new treatment for congestive heart failure

CT-011 completes phase I study in advanced hematological malignancies

Intercell and Biological E sign Asia agreement for Japanese encephalitis vaccine

FDA clears phase I study of systemic administered Reolysin

AustCancer submits DMF for GPI-0100

Innovate Oncology acquires rights to Capridine-Beta for prostate cancer

BAL-5788 enters hospital-acquired pneumonia phase III trials

Fosamax Plus D receives FDA approval

Celgene completes Revlimid NDA submission for MDS

Eisai and Abbott to develop adalimumab for psoriasis in Japan

Bausch & Lomb discloses new therapeutic agents for ophthalmic diseases

Retisert receives FDA approval

New patents cover treatments for pain and inflammation

New data on the antiviral efficacy and the PK of celgosivir

Long-term effects of transdermal rotigotine in patients with early PD

A new study confirms the benefits of eszopiclone in chronic insomnia

Lasofoxifene induces no adverse effects on mood and cognition in postmenopausal women

Japanese manufacturing approval for tocilizumab for Castleman's disease

Japanese manufacturing approval for Lulicon

Promising results from in vitro and in vivo testing of human rhinovirus inhibitor

Prana will not advance PBT-1 into PLACQUE study

Long-acting naltrexone reduces heavy drinking in alcohol-dependent subjects

Phase III results on lucinactant in premature infants at risk for RDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.